- Specialization
Biotechnologyand 1 more specialization valuesLess
- Scientific Discovery
- Business
- Scientific Research
- Market
- Life Sciences
- Ecosystem
- Not applicable
- Customers
- Not classified
More details
- Organization type
- Commercial Company
- Ecosystem
- Not applicable
- Business
- Scientific Research
- Specialization
- Biotechnology, Scientific Discovery
- Market
- Life Sciences
- Customers
- Not classified
- Delivery models
- Not classified
- Revenue models
- Grants
- Listing status
- Not classified
- Latest equity round
- Not classified
- Reported funding amount
- Not classified
About
Eugit Therapeutics develops tissue-targeting therapies designed to improve the safety and efficacy of drugs that otherwise affect healthy tissues. Its TAGHOME platform uses T-cell receptors to direct therapies toward diseased tissues, with an initial focus on inflammatory bowel disease and additional work on engineered immune-cell therapies for cancer.
Market
Eugit competes in the precision-medicine and gamma-delta T-cell cancer-immunotherapy markets, with an adjacent tissue-targeted therapeutic-delivery application for inflammatory bowel disease. Its positioning combines TCR-based delivery to diseased tissue with gene-engineered, donor-derived gamma-delta T cells intended to be off-the-shelf, initially targeting breast, ovarian, and prostate cancers. Compared with gamma-delta competitors focused primarily on CAR-T cells, T-cell engagers, or unmodified donor cells, Eugit’s stated differentiation is the combination of tissue targeting and engineered allogeneic cell therapy, although the available evidence indicates an early-stage development program rather than a clinically validated product.
Eugit’s primary commercial customers are established pharmaceutical and biotechnology companies, especially oncology, immunology, and precision-medicine R&D or business-development teams seeking partnered therapeutic platforms. The end beneficiaries are patients with difficult-to-treat cancers such as breast, ovarian, and prostate cancer, as well as patients with treatment-resistant inflammatory bowel disease.
At a Glance
Problem
Eugit Therapeutics addresses the limitations of non-specific drug treatment for tissue-specific inflammatory disease. In inflammatory bowel disease (IBD), broad therapies can cause severe side effects and may fail to reach or act selectively on diseased tissue, contributing to poor outcomes and clinical-trial failures. The initial use case is the roughly 3.1 million U.S. adults with IBD, especially the estimated 5–10% who do not respond to existing treatments; Eugit describes this refractory segment as representing an opportunity of approximately $4.65 billion.
Product / Service
Eugit’s platform, described as TAGHOME, is intended to deliver therapeutic payloads precisely to diseased tissue using T-cell receptors. Its current development program seeks to identify agents that accumulate in the gastrointestinal tract, validate their localization and retained functionality in macaques, and ultimately pair those targeting agents with therapeutic compounds. The intended benefit is greater treatment precision, improved efficacy, and fewer systemic adverse effects, with potential applications beyond IBD.
Market
Eugit competes in precision medicine, tissue-specific drug delivery, and IBD therapeutics. Its practical alternatives include established broad biologics such as infliximab, adalimumab, and certolizumab pegol, as well as emerging site-specific delivery systems; the available evidence does not identify a direct named competitor to TAGHOME. Eugit’s public materials also retain an earlier description of an off-the-shelf gamma-delta T-cell cancer-immunotherapy program for breast, ovarian, and prostate cancers, suggesting that its positioning has evolved toward tissue-targeted payload delivery and IBD.
The company appears pre-revenue and pre-commercial rather than clinically validated: its disclosed work is centered on a proof of concept and a planned later Phase II program, while its stated objective was to initiate clinical trials within two years. Its traction is primarily scientific and financing-related, including Y Combinator’s Summer 2022 backing, cofounding by George Church, and a $275,000 NSF SBIR Phase I award running from August 2024 through an estimated July 2026 end date.
Founders & Leadership
Funding History
Y Combinator
National Science Foundation
Recent News
Eugit Therapeutics is described as working on its first indication, pediatric liver cancer (hepatoblastoma), with partners at Texas Children’s Hospital. The listing characterizes the hospital as having world-leading expertise in the area.
A medRxiv clinical-trial report states that one contributor, identified as YF, has a financial interest in Eugit Therapeutics. The report was posted on March 9, 2026.
Active Roles
0No active roles right now.
Get notified when they postBusiness Model
Eugit is an early-stage therapeutics company funding research and development through venture and grant financing, including Y Combinator and an NSF grant. No commercial pricing or recurring-revenue model is disclosed; eventual revenue would likely come from commercializing or licensing its therapeutic products.